(1-743)-(1638-2332)-BLOOD-COAGULATION FACTOR VIII (SYNTHETIC HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT), (1444-6'),(1447-9')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT)
Hemophilia A
Explore 62 assets in Hemophilia A →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Margaret Ragni
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04303572CT.gov The Hemophilia Inhibitor Eradication Trial | — | Terminated | — | — | — |
NCT04303559CT.gov The Hemophilia Inhibitor Prevention Trial | — | Terminated | — | — | — |
NCT04728217CT.gov Health Related Quality of Life of Youth and Young Adults With Haemophilia A | — | Completed | — | — | — |
NCT04690322CT.gov POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies | — | Withdrawn | — | — | — |
NCT04293523CT.gov A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health | — | Active Not Recruiting | — | — | — |
NCT03364998CT.gov BAY94-9027 PK Study Comparing to Another Long Acting Product | — | Completed | — | — | — |
NCT03103542CT.gov Study of rFVIIIFc for Immune Tolerance Induction (ITI) in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies | — | Completed | — | — | — |
NCT03055611CT.gov A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B | — | Completed | — | — | — |
NCT02976753CT.gov Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hemophilia A
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (1-743)-(1638-2332)-BLOOD-COAGULATION FACTOR VIII (SYNTHETIC HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT), (1444-6'),(1447-9')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT) (this asset) | Margaret Ragni | Approved | BB · 66 |
| Turoctocog Alfa | Novo Nordisk A/S | P4 | A |
| Eptacog Alfa (Activated) | AryoGen Pharmed Co. | P4 | A |
| Rurioctocog Alfa Pegol | Takeda | P4 | BBB |
| Immunoglobulin G4 [230-Proline,De-449-Lysine], Anti-(Human Blood-Coagulation Factor Ix)(Human Clone 0365-0001-9985 ?4-Chain), Disulfide With Human Clone 0365-0001-9985 ?-Chain, (228?226?),(231?229?)-Bis(Disulfide) With Anti-(Human Blood-Coagulation Factor X) Immunoglobulin G4 [228-Proline,405-Leucine,409-Lysine,De-447-Lysine] (Human Clone 0365-0001-8174 ?4-Chain) Disulfide With Human Clone 0365-0001-8174 ?-Chain | Novo Nordisk A/S | P3 | BBB |
| N8-GP | Novo Nordisk A/S | P3 | BBB |
| bay94-9027 | Bayer | P4 | BBB |
| Emicizumab | Emory University | P4 | BBB |
| Factor Viii (Human) | Hoffmann-La Roche | P4 | BBB |
+36 more in the Hemophilia A cohort
Other indications for (1-743)-(1638-2332)-BLOOD-COAGULATION FACTOR VIII (SYNTHETIC HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT), (1444-6'),(1447-9')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Severe Hemophilia A | — | P3 | B · 59 |
| Hemophilia B | — | Unk | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Turoctocog AlfaNovo Nordisk A/SA
- Eptacog Alfa (Activated)AryoGen Pharmed Co.A
- Rurioctocog Alfa PegolTakedaBBB
- Immunoglobulin G4 [230-Proline,De-449-Lysine], Anti-(Human Blood-Coagulation Factor Ix)(Human Clone 0365-0001-9985 ?4-Chain), Disulfide With Human Clone 0365-0001-9985 ?-Chain, (228?226?),(231?229?)-Bis(Disulfide) With Anti-(Human Blood-Coagulation Factor X) Immunoglobulin G4 [228-Proline,405-Leucine,409-Lysine,De-447-Lysine] (Human Clone 0365-0001-8174 ?4-Chain) Disulfide With Human Clone 0365-0001-8174 ?-ChainNovo Nordisk A/SBBB
- N8-GPNovo Nordisk A/SBBB
Citation
Floatz Terminal. (1-743)-(1638-2332)-BLOOD-COAGULATION FACTOR VIII (SYNTHETIC HUMAN) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT), (1444-6'),(1447-9')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN FC DOMAIN FRAGMENT) in Hemophilia A. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/1-743-1638-2332-blood-coagulation-factor-viii-synthetic-human-fusion-protein-with-immunoglobulin-g1-synthetic-human-fc-domain-fragment-1444-61447-9-bisdisulfide-with-immunoglobulin-g1-synthetic-human-fc-domain-fragment-hemophilia-a
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →